ERBB2 and neoplasm: Trastuzumab deruxtecan, a monoclonal antibody against Her-2 linked with a topoisomerase I inhibitor, has recently been approved by FDA for the treatment of pre-treated advanced Her-2-expressing (IHC 3+) neoplasms, based on the results of the DESTINY-PanTumor02, DESTINY-Lung02 and DESTINY-CRC01 trials [12, 110, 111].